EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 56 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ESMO Virtual Congress 2020, 19-21 September [ESMO Media Alert] July 27, 2020 New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 Boy Asks Mom Fighting Cancer To Take Off Her Turban So... May 4, 2020 Could proton beam therapy improve throat cancer treatment? March 15, 2021 Load more HOT NEWS A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies Q&A: Learning About the Cancer Care Challenges LGBTQ+ People Face
